Andrew Berchuck, MD



email this

Professor of Obstetrics and Gynecology
Director, Division of Gynecologic Oncology
Department / Division:
Obstetrics/Gynecology / Gynecology Oncology
DUMC 3079
Durham, NC 27710
Appointment Telephone:
Office Telephone:
  • MD, Case Western Reserve University School of Medicine (Ohio), 1980
  • OB-GYN, Case Western Reserve University (Ohio), 1980-1984
  • Gynecologic Oncology, Sloan-Kettering Cancer Center (New York), 1985-1987
Clinical Interests:
Gynecologic malignancies, premalignant diseases of the cervix and vagina, radical pelvic surgery, chemotherapy, radiation therapy, reconstructive pelvic surgery, laser surgery, complicated gynecologic surgery, hereditary ovarian and endometrial cancer, minimally invasive laparoscopic surgery
Research Interests:
Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the F. Bayard Carter Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund ( in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (
Representative Publications:
  • Baba, T; Convery, PA; Matsumura, N; Whitaker, RS; Kondoh, E; Perry, T; Huang, Z; Bentley, RC; Mori, S; Fujii, S; Marks, JR; Berchuck, A; Murphy, SK. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene: Including Oncogene Reviews. 2009;28:209-218.  Abstract
  • Berchuck, A; Iversen, ES; Luo, J; Clarke, JP; Horne, H; Levine, DA; Boyd, J; Alonso, MA; Secord, AA; Bernardini, MQ; Barnett, JC; Boren, T; Murphy, SK; Dressman, HK; Marks, JR; Lancaster, JM. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15:2448-2455.  Abstract
  • Schildkraut, JM; Goode, EL; Clyde, MA; Iversen, ES; Moorman, PG; Berchuck, A; Marks, JR; Lissowska, J; Brinton, L; Peplonska, B; Cunningham, JM; Vierkant, RA; Rider, DN; Chenevix-Trench, G; Webb, PM; Beesley, J; Chen, X; Phelan, C; Sutphen, R; Sellers, TA; Pearce, L; Wu, AH; Van Den Berg, D; Conti, D; Elund, CK; Anderson, R; Goodman, MT; Lurie, G; Carney, ME; Thompson, PJ; Gayther, SA; Ramus, SJ; Jacobs, I; Kr├╝ger Kjaer, S; Hogdall, E; Blaakaer, J; Hogdall, C; Easton, DF; Song, H; Pharoah, PD et al.. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Research. 2009;69:2349-2357.  Abstract
  • Berchuck, A. Scientific innovation--pathway to progress in women's cancer. Gynecologic Oncology. 2008;109:316-322.  Abstract
  • Havrilesky, LJ; Whitehead, CM; Rubatt, JM; Cheek, RL; Groelke, J; He, Q; Malinowski, DP; Fischer, TJ; Berchuck, A. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecologic Oncology. 2008;110:374-382.  Abstract
  • Palmieri, RT; Wilson, MA; Iversen, ES; Clyde, MA; Calingaert, B; Moorman, PG; Poole, C; Anderson, AR; Anderson, S; Anton-Culver, H; Beesley, J; Hogdall, E; Brewster, W; Carney, ME; Chen, X; Chenevix-Trench, G; Chang-Claude, J; Cunningham, JM; Dicioccio, RA; Doherty, JA; Easton, DF; Edlund, CK; Gayther, SA; Gentry-Maharaj, A; Goode, EL; Goodman, MT; Kjaer, SK; Hogdall, CK; Hopkins, MP; Jenison, EL; Blaakaer, J; Lurie, G; McGuire, V; Menon, U; Moysich, KB; Ness, RB; Pearce, CL; Pharoah, PD et al.. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008;17:3567-3572.  Abstract
  • Pearce, CL; Wu, AH; Gayther, SA; Bale, AE; Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group, ; Beck, PA; Beesley, J; Chanock, S; Cramer, DW; DiCioccio, R; Edwards, R; Fredericksen, ZS; Garcia-Closas, M; Goode, EL; Green, AC; Hartmann, LC; Hogdall, E; Kjaer, SK; Lissowska, J; McGuire, V; Modugno, F; Moysich, K; Ness, RB; Ramus, SJ; Risch, HA; Sellers, TA; Song, H; Stram, DO; Terry, KL; Webb, PM; Whiteman, DC; Whittemore, AS; Zheng, W; Pharoah, PD; Chenevix-Trench, G et al.. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. British Journal of Cancer. 2008;98:282-288.  Abstract
  • Schildkraut, JM; Moorman, PG; Bland, AE; Halabi, S; Calingaert, B; Whitaker, R; Lee, PS; Elkins-Williams, T; Bentley, RC; Marks, JR; Berchuck, A. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008;17:585-593.  Abstract
  • Dressman, HK; Berchuck, A; Chan, G; Zhai, J; Bild, A; Sayer, R; Cragun, J; Clarke, J; Whitaker, RS; Li, L; Gray, J; Marks, J; Ginsburg, GS; Potti, A; West, M; Nevins, JR; Lancaster, JM. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. Journal of Clinical Oncology. 2007;25:517-525.  Abstract
  • Spillman, MA; Lacy, J; Murphy, SK; Whitaker, RS; Grace, L; Teaberry, V; Marks, JR; Berchuck, A. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. Gynecologic Oncology. 2007;105:312-320.  Abstract
  • Bild, AH; Yao, G; Chang, JT; Wang, Q; Potti, A; Chasse, D; Joshi, MB; Harpole, D; Lancaster, JM; Berchuck, A; Olson, JA; Marks, JR; Dressman, HK; West, M; Nevins, JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439:353-357.  Abstract
  • Guillem, JG; Wood, WC; Moley, JF; Berchuck, A; Karlan, BY; Mutch, DG; Gagel, RF; Weitzel, J; Morrow, M; Weber, BL; Giardiello, F; Rodriguez-Bigas, MA; Church, J; Gruber, S; Offit, K; ASCO, ; SSO. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Journal of Clinical Oncology. 2006;24:4642-4660.  Abstract
  • Jewell, E; Secord, AA; Brotherton, T; Berchuck, A. Use of trastuzumab in the treatment of metastatic endometrial cancer. International Journal of Gynecological Cancer. 2006;16:1370-1373.  Abstract
  • Potti, A; Dressman, HK; Bild, A; Riedel, RF; Chan, G; Sayer, R; Cragun, J; Cottrill, H; Kelley, MJ; Petersen, R; Harpole, D; Marks, J; Berchuck, A; Ginsburg, GS; Febbo, P; Lancaster, J; Nevins, JR. Genomic signatures to guide the use of chemotherapeutics. Nature Medicine. 2006;12:1294-1300.  Abstract
  • Schildkraut, JM; Moorman, PG; Halabi, S; Calingaert, B; Marks, JR; Berchuck, A. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006;17:104-107.  Abstract
  • Berchuck, A; Iversen, ES; Lancaster, JM; Pittman, J; Luo, J; Lee, P; Murphy, S; Dressman, HK; Febbo, PG; West, M; Nevins, JR; Marks, JR. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005;11:3686-3696.  Abstract
  • Cragun, JM; Havrilesky, LJ; Calingaert, B; Synan, I; Secord, AA; Soper, JT; Clarke-Pearson, DL; Berchuck, A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. Journal of Clinical Oncology. 2005;23:3668-3675.  Abstract
  • Spillman, MA; Schildkraut, JM; Halabi, S; Moorman, P; Calingaert, B; Bentley, RC; Marks, JR; Murphy, S; Berchuck, A. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecologic Oncology. 2005;97:543-549.  Abstract
  • Berchuck, A; Schildkraut, JM; Wenham, RM; Calingaert, B; Ali, S; Henriott, A; Halabi, S; Rodriguez, GC; Gertig, D; Purdie, DM; Kelemen, L; Spurdle, AB; Marks, J; Chenevix-Trench, G. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2004;13:2141-2147.  Abstract
  • Havrilesky, L; Darcy, KM; Hamdan, H; Priore, RL; Leon, J; Bell, J; Berchuck, A; Gynecologic Oncology Group Study. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2003;21:3814-3825.  Abstract